FDA
-
-
-
-
-
-
-
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
-
-
-
-
-
-
-
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
-
-
-
-
-
-
-
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
-
-
-
-
-
-
-
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)
-
-
-
-
-
-
-
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil
-
-
-
-
-
-
-
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
-
327,804 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

